Heart failure drug shows promise for Non-Diabetic patients

NCT ID NCT05562063

Completed Disease control Sponsor: Juan Badimon Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the drug sotagliflozin can improve heart function in people with a type of heart failure called HFpEF who do not have diabetes. Eighty-eight participants took either the drug or a placebo for six months. Researchers used heart scans and exercise tests to measure changes in heart structure and function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sotagliflozin
What this could lead to: If successful, this could point toward a new treatment option for heart failure patients without diabetes, potentially improving heart function and quality of life.
What could go wrong: This is a small, early-phase trial with only 88 participants, so results may not apply to everyone. The drug may not show significant benefits, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH PRESERVED EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diastolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE WITH PRESERVED EJECTION FRACTION

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.